2026 Annual Meeting | PL6 - Contemporary Clinical Issues Plenary Session

Date Wednesday 04/22/26

Time 09:15 AM - 11:00 AM CDT Add To Calendar

Location McCormick Place West | W375de

Session Format This program will be presented both in-person and online

On Demand This program will be available in the meeting's On Demand product.

Event Type Plenary Session

Director(s) Chad Hales, MD, PhD, F�鶹��ýӳ��

Topic(s) General Neurology, Movement Disorders, Practice, Policy, and Ethics, Aging, Dementia, and Behavioral Neurology, Multiple Sclerosis

Learning Objectives This session highlights issues most critical to practicing neurologists, including abstracts related to new therapeutic developments, clinical applications of basic and translational research, and innovative technical developments already affecting the practice of neurology.

CME Available 1.75 CME credits

Program Tracks Artificial Intelligence, Medical Students, Residents

Program Materials Program Evaluations

Event Timeline
09:15 AM - 09:25 AM CDT	Speaker	Presenter: AMT-130 Huntington’s Disease Gene Therapy: Clinical Study Outcomes at 3 Years Victor W. Sung, MD
09:25 AM - 09:35 AM CDT	Speaker	Discussant: AMT-130 Huntington’s Disease Gene Therapy: Clinical Study Outcomes at 3 Years Yvette Bordelon, MD, PhD, F�鶹��ýӳ��
09:35 AM - 09:45 AM CDT	Speaker	Presenter: Bridging the Knowledge Gap: Real-world Implementation of an AI Clinical Assistant in Neurology Mikael Guzman Karlsson, MD, PhD
09:45 AM - 09:55 AM CDT	Speaker	Disussant: Bridging the Knowledge Gap: Real-world Implementation of an AI Clinical Assistant in Neurology Lidia Maria V. Moura, MD, PhD, MPH, F�鶹��ýӳ��
09:55 AM - 10:05 AM CDT	Speaker	Presenter: Efficacy and Safety of Tolebrutinib Versus Placebo in Primary Progressive Multiple Sclerosis: Results from the Phase 3 PERSEUS Trial Robert J. Fox, MD, F�鶹��ýӳ��
10:05 AM - 10:15 AM CDT	Speaker	Discussant: Efficacy and Safety of Tolebrutinib Versus Placebo in Primary Progressive Multiple Sclerosis: Results from the Phase 3 PERSEUS Trial Farrah J. Mateen, MD, PhD, F�鶹��ýӳ��
10:15 AM - 10:25 AM CDT	Speaker	Presenter: Lifestyle Interventions vs. Monoclonal Antibodies in Mild Cognitive Impairment and Early Alzheimer’s Disease: A Comparative Review of Randomized Controlled Trials Majid Fotuhi, MD, PhD
10:25 AM - 10:35 AM CDT	Speaker	Discussant: Lifestyle Interventions vs. Monoclonal Antibodies in Mild Cognitive Impairment and Early Alzheimer’s Disease: A Comparative Review of Randomized Controlled Trials Neelum T. Aggarwal, MD
10:35 AM - 10:45 AM CDT	Speaker	Presenter: Enhancing Glymphatic Transport via Vasopressin: Implications of Neurodegenerative Disease and Drug Delivery Eman Hamed, MD, PhD
10:45 AM - 10:55 AM CDT	Speaker	Discussant: Enhancing Glymphatic Transport via Vasopressin: Implications of Neurodegenerative Disease and Drug Delivery Humberto Mestre, MD, PhD

Faculty Disclosures
Chad Hales, MD, PhD, F�鶹��ýӳ��	The institution of Dr. Hales has received research support from BrightFocus foundation. The institution of Dr. Hales has received research support from NIH. The institution of Dr. Hales has received research support from State of Georgia. Dr. Hales has a non-compensated relationship as a committee member with �鶹��ýӳ�� that is relevant to �鶹��ýӳ�� interests or activities.
Robert J. Fox, MD, F�鶹��ýӳ��	Dr. Fox has received personal compensation in the range of $500-$4,999 for serving as a Consultant for AB Science. Dr. Fox has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Biogen. Dr. Fox has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for BMS. Dr. Fox has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for EMD Serono. Dr. Fox has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Genentech. Dr. Fox has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Immunic. Dr. Fox has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Novartis. Dr. Fox has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Sanofi. Dr. Fox has received personal compensation in the range of $500-$4,999 for serving as a Consultant for TG Therapeutics. Dr. Fox has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Siemens. Dr. Fox has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Roche. Dr. Fox has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Astoria Biologica. Dr. Fox has received personal compensation in the range of $500-$4,999 for serving as a Consultant for InnoCare Pharma. Dr. Fox has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Biogen. Dr. Fox has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Immunic. Dr. Fox has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Novartis. Dr. Fox has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for AB Science. Dr. Fox has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Sanofi. Dr. Fox has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for BMS. The institution of Dr. Fox has received research support from National Institutes of Health. The institution of Dr. Fox has received research support from National MS Society. Dr. Fox has received publishing royalties from a publication relating to health care.
Majid Fotuhi, MD, PhD	Dr. Fotuhi has nothing to disclose.
Lidia Maria V. Moura, MD, PhD, MPH, F�鶹��ýӳ��	Dr. Moura has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for UCB. Dr. Moura has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Pfizer. The institution of Dr. Moura has received research support from Centers for Diseases Control and Prevention (CDC SIP20-007) . The institution of Dr. Moura has received research support from Epilepsy Foundation of America . The institution of Dr. Moura has received research support from NIH - NIA and NINDS. Dr. Moura has received personal compensation in the range of $50,000-$99,999 for serving as a Expert Advisor with Epilepsy Foundation .
Victor W. Sung, MD	Dr. Sung has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Teva Neuroscience. Dr. Sung has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Genentech. Dr. Sung has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Neurocrine. Dr. Sung has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for UniQure.
Mikael Guzman Karlsson, MD, PhD	An immediate family member of Dr. Guzman Karlsson has received personal compensation for serving as an employee of Thea Pharma, Inc..
Eman Hamed, MD, PhD	Dr. Hamed has nothing to disclose.
Farrah J. Mateen, MD, PhD, F�鶹��ýӳ��	Dr. Mateen has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Amgen. Dr. Mateen has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Genentech. Dr. Mateen has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Novartis. The institution of Dr. Mateen has received research support from Genentech. The institution of Dr. Mateen has received research support from Amgen. The institution of Dr. Mateen has received research support from TG Therapeutics. Dr. Mateen has received intellectual property interests from a discovery or technology relating to health care.
Humberto Mestre, MD, PhD	The institution of Dr. Mestre has received research support from Brain Aneurysm Foundation. The institution of Dr. Mestre has received research support from National Institute of Health. Dr. Mestre has received intellectual property interests from a discovery or technology relating to health care.
Neelum T. Aggarwal, MD	Dr. Aggarwal has nothing to disclose.
Yvette Bordelon, MD, PhD, F�鶹��ýӳ��	Dr. Bordelon has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Tolmar. The institution of Dr. Bordelon has received research support from Amylyx .